Modelling antisepsis using defined populations of facultative and anaerobic wound pathogens grown in a basally perfused biofilm model by Oates, Angela. et al.
1Modelling antisepsis using defined populations of facultative1
and anaerobic wound pathogens grown in a2
basally perfused biofilm model3
4
Angela Oatesa#, Sharon Lindsayb, Hitesh Mistrya, Fernando Ortegaa, Andrew J McBaina*5
6
aDivision of Pharmacy and Optometry School of Health Sciences,7
Faculty of Biology, Medicine and Health, The University of Manchester.8
bSystagenix, Gargrave, North Yorkshire, BD23 3RX9
10
#Present address: School of Healthcare, Faculty of Medicine and Health,11
The University of Leeds, Leeds, U.K.12
13
14
15
16
17
18
Key words: Wound biofilm, in vitro model, MRSA, anaerobic, antisepsis19
Running head: Modelling wound antisepsis20
21
22
23
24
25
26
27
28
29
30
31
32
33
*Corresponding author: Andrew McBain, Division of Pharmacy and Optometry, School of Health34
Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M1335
9PT, UK. Tel: (44)161 275 2360; Email: andrew.mcbain@manchester.ac.uk36
37
This is an Accepted Manuscript of an article published by Taylor & Francis in Biofouling on 6 Jun 
2018, available online: http://www.tandfonline.com/10.1080/08927014.2018.1466115.
2Abstract38
An in vitro model was developed to assess the effects of topical antimicrobials on taxonomically39
defined wound biofilms. Biofilms were exposed over 7d to povidone-iodine, silver acetate or40
polyhexamethylene biguanide (PHMB) at concentrations used in wound dressings. The rank order of41
susceptibility in multi-species biofilms, based on an analysis of the average bacterial counts over42
time (low to high) was P. aeruginosa>Methicillin-resistant Staphylococcus aureus (MRSA)>B.43
fragilis>S. pyogenes. The rank order of effectiveness for the antimicrobials in the biofilm model was44
povidone-iodine>PHMB>silver acetate. None of the test compounds eradicated P. aeruginosa or45
MRSA from the biofilms although all compounds except silver acetate eliminated S. pyogenes.46
Antimicrobial effectiveness against bacteria grown in multi-species biofilms did not correlate with47
planktonic susceptibility. Defined biofilm populations of mixed-species wound pathogens could be48
maintained in the basal perfusion model, facilitating the efficacy testing of treatments regimens and49
potential dressings against multi-species biofilms composed of wound isolates.50
51
352
Introduction53
Chronic wounds represent a considerable challenge to wound care professionals and healthcare54
resources, having a significant bearing upon patient morbidity and mortality (Scali and Kunimoto55
2013). Whilst the processes influencing the transition to a chronic wound state are complex and56
depend on host factors such as wound aetiology, co-morbidities and anatomical location, infection57
and the presence of biofilms have been implicated as important contributors (Roy et al. 2014, Scali58
and Kunimoto 2013, Schierle et al. 2009). Biofilms have been described as structured microbial59
communities encased in an exopolymer matrix (Costerton 1999, Hall-Stoodley et al. 2004) that are60
normally taxonomically diverse and adapted to survive inimical conditions (Gilbert et al. 2002,61
Watanabe et al. 1998). Evidence suggests that through cellular proximity, biofilm formation can62
enhance horizontal gene transfer rates and may therefore drive bacterial the transfer of resistance63
determinants (Hausner and Wuertz 1999, Sorensen et al. 2005) and microbial evolution over longer64
timescales (as reviewed by Claessen et al., 2014). Through genotypic and phenotypic heterogeneity,65
biofilms exhibit substantially increased tolerance to antimicrobial therapies and host immune66
responses (Gilbert et al. 2002, Pedersen 1992, Stewart and Costerton 2001).67
68
The association of biofilms with chronic wounds (Bjarnsholt et al. 2008, Kanno et al. 2009, Neut et69
al. 2011, Roy et al. 2014, Wolcott and Rhoads 2008) has driven the development and application of70
antimicrobial dressings based on their effectiveness against the most recalcitrant forms of microbial71
growth present in this environment, which includes organisms displaying biochemical resistance,72
such as Pseudomonas spp. (Ramos et al. 2010, Rochex and Lebeault 2007, Walters et al. 2003),73
Methicillin resistant Staphylococcus aureus (MRSA) (McCarthy et al. 2015, Ohadian Moghadam et74
al. 2014) and microbial biofilms, that generally exhibit greater tolerance to antimicrobials than their75
planktonic counterparts regardless of taxonomic composition (Gilbert et al. 2002).76
4A variety of antimicrobial wound dressings are available incorporating active compounds such as77
iodine and silver that are designed with broad-spectrum antimicrobial activity in mind (Barnea et al.78
2010, Bradley et al. 1999, Butcher 2012). In vitro models supporting the growth of biofilm79
communities (Oates and McBain 2016) can be used in the preclinical investigation of antimicrobial80
dressings for their potential effectiveness against wound bacteria (Humphreys et al. 2011, Werthén et81
al. 2010, Wilkinson et al. 2016, Woods et al. 2012). Several models have been developed specifically82
for investigating wound-associated biofilms, including the Lubbock Chronic Wound Biofilm, which83
is a closed, static media system (Sun et al. 2008), a flat-bed perfusion model that comprises a84
continuous media flow system with an inert substratum (Thorn and Greenman 2009), and the85
modified drip-slide reactor (Lipp et al. 2010). Various other continuous culture systems have also86
been developed for biofilm applications including the Constant Depth Film Fermenter (CDFF) and87
devices housing Sorbarods (cylindrical cellulose filters). These models have been used for a range of88
applications including wound biofilm investigations (Hill et al. 2010, Hodgson et al. 1995). Axenic89
or combined cultures of bacteria of relevance to wounds such as Staphylococcus aureus and90
Pseudomonas aeruginosa have been utilised in in vitro models in several previous investigations91
(Oates and McBain 2016, Thorn and Greenman 2009, Werthén, Henriksson, Jensen, Sternberg,92
Givskov and Bjarnsholt 2010) and can generate robust and reproducible data, allowing for example,93
the examination of axenic biofilm growth dynamics and responses to antimicrobials. Defined94
community systems where a small number of culturable bacteria are grown together in a biofilm95
model are however, likely to be more representative of the communities which they aim to represent96
as opposed to single species systems (Thorn and Greenman 2009).97
98
In the current investigation, a model in which the effectiveness of topical antimicrobials can be99
assessed against four functionally distinct wound pathogens grown together in biofilms was100
developed. The system has several features of use for preclinical evaluation of antimicrobials for101
5application to wounds since biofilms grown in the system are fed basally like the nutrient supply in102
chronic wounds, and it supports the growth of obligate aerobic, anaerobic and facultative bacterial103
organisms, enabling assessment of the differential effects of distinct classes of antimicrobial against104
broad physiological groups of wound pathogens.105
106
Methods107
Bacteria108
Four bacteria of significance to wound infections and with variable growth requirements were109
selected for inclusion in the defined biofilm consortium. Pseudomonas aeruginosa and110
Streptococcus pyogenes were isolated from infected wounds. Methicillin resistant Staphylococcus111
aureus (MRSA) NCTC 11939 and Bacteriodes fragilis NCTC 9343 were obtained from Public112
health England Southampton, UK.113
114
Chemicals and media115
Vantocil (a 20% [vol/vol] aqueous solution of polyhexamethylene biguanide) was obtained from116
Arch Biocides, Inc. (Manchester, United Kingdom). Dehydrated bacteriological media were obtained117
from Oxoid (Basingstoke, Hampshire, U.K.) and reconstituted per instructions supplied by the118
manufacturer. Unless otherwise stated all other chemicals used were supplied by Sigma (Poole,119
Dorset, U.K.).120
121
Model Development and Optimisation122
Relative fitness assays123
To assess whether the four bacterial strains selected for the mixed wound consortium could grow124
stably when combined, relative fitness was assessed in pair-wise combinations during growth on125
5mm x 5mm mono-acetate filters (BullBrand Ltd. Keighthly, UK) using a modified competition126
6assay (Lenski et al. 1991, Rozen et al. 2007), as follows: stationary phase cultures were grown127
overnight in a simulated wound fluid (SWF) medium consisting of foetal calf serum (49% v/v),128
Mueller-Hinton broth (49% v/v) and laked horse blood (2% v/v). Axenic cultures were then adjusted129
to achieve an initial inoculum density of c. 1 x 108 CFU/ml and combined in a 1:1 ratio with a130
partner culture and then further diluted in fresh sterile SWF to give a final density of c. 1 x 106131
CFU/ml. The final combined inoculum was dispensed (1 ml) onto 5mm x 5mm monoacetate filters132
(n=6) housed within the wells of a microtitre plate. To determine the initial starting CFU/mm3 of133
each bacterial isolate, three filters were aseptically removed, aseptically sectioned, with sections134
placed in a plastic Universal bottle (Scientific Laboratory Supplies, Nottingham, UK) containing 9135
ml of half-strength Thiogylcolate Broth and 5 mm sterile glass beads (n = 5) (Merck, Darmstadt,136
Germany). To ensure uniform distribution of cells throughout the diluent, Universals were vortexed137
for 10 sec., serially diluted in half strength thioglycolate broth and plated onto suitable selective138
agars, as follows: Mannitol Salt Agar, Pseudomonas CFC selective agar, G-N Anaerobe Selective139
Agar and Streptococcus Selective Agar. The remaining filters were incubated for 48 h and then140
viable counts were performed to determine the endpoint CFU/mm3.141
142
Basal perfusion wound biofilm models143
A diagram of the basal perfusion model is shown in Figure 1 and 2. Briefly, the system consists of a144
hollow cylinder Pyrex glass outer casing (8 cm Ø x 4.5 cm depth) housing three machined145
polytetrafluoroethylene (PTFE) components comprising a lid, a central receptacle and a waste146
reservoir. The lid measures c. 8 cm Ø and contains a central inlet tube to deliver media to the central147
receptacle. The central receptacle is machined from PTFE and contains a central fluid basin (2.2 cm148
Ø x 3 cm), which is fed with media via the lid inlet tube (Figure 1). There are 8 channels that lead149
away from the central fluid basin towards 8 individual filter receptacles (1 cm Ø) where each filter150
resides. Each filter receptacle incorporates a lower fluid bulk section and an upper level receptacle151
7separated by a small PTFE rim (0.5 cm Ø) upon which 5mm x 5mm mono-acetate filters (Bullbrand152
Ltd. Keighthly, UK) are placed. Medium fed into the central fluid basin is distributed into the lower153
fluid bulk section of the filter receptacles via the channels shown in Figure 1. The fibres of the 5mm154
x 5mm mono-acetate filter act as a wick, drawing media up from the bulk fluid, saturating the filter.155
Drainage channels leading away from the filter receptacles allow the removal of excess media and156
waste products into the waste reservoir, where it is drained from the whole system via the outlet tube157
in the Pyrex glass casing. Temperature (37°C) and atmosphere (O2) were maintained by placing the158
device in an aerobic incubator. SWF was continually supplied to the device at a rate of c. 1.5 ± 0.1159
ml h-1 by peristaltic pump (Minipulse 3, Gilson, Villiers-Le-Bel, France). Once inoculated with all160
four bacteria, the model was run for up to 8 days.161
162
Inoculation and population stability assays163
Initial trials into the inoculation and maintenance of the defined wound consortium (MRSA, S.164
pyogenes, P. aeruginosa and B. fragilis) determined that a staggered inoculation process was165
required (data not shown). Prior to inoculation, the system was preconditioned with SWF for 1 h.166
Stationary phase axenic cultures of MRSA and S. pyogenes were each adjusted to give an inoculum167
density of c. 1 x 108 CFU/ml, combined in a 1:1 ratio and a further diluted to give cellular density of168
each organism of c. 1 x 107 CFU/ml. Filters were inoculated in situ with 1 ml of the dual species169
inoculum. The basal perfusion model was continuously fed at a rate of 1.5 ± 0.1 ml h-1 by peristaltic170
pump. After 24 h, stationary phase cultures of P. aeruginosa and B. fragilis were similarly adjusted171
and combined to give a density of c. 1 x 107 CFU/ml of each organism and 1 ml of this mixed172
inoculum was used to inoculate each filter. The model was incubated for a further 24 h under173
continuous culture conditions before sampling. Filters were then removed every 24 h and placed in 9174
ml of half strength thioglycolate broth containing 5 mm sterile glass beads (n=5) (Merck, Darmstadt,175
Germany), vortexed for 10 s, serially diluted in half strength thioglycolate broth and plated onto176
8suitable selective agar as follows to allow for viable counts of each distinct organism, as outlined177
above. All experiments were undertaken independently, in triplicate.178
179
Homogeneity of population densities across filters180
The basal perfusion model was designed to grow wound associated bacterial communities and assess181
the response to antimicrobial therapies over time. To ensure that the population densities in each182
filter were homogenous with those in the other filters i.e. a population density of a randomly sampled183
filter would be approximately the same in another filter within the same model, several independent184
basal perfusion models were set up as previously described and run to a timed endpoint. Four filters185
were randomly selected and removed at each end-point and viable counts preformed as previously186
described. This was continued until viable count data for 4 filters for each individual day over 8 d187
were completed. Statistical significance was determined using analysis of variance (ANOVA)188
combined with post-hoc analysis of least significant difference (LSD) test to determine significant189
difference.190
191
Imaging of biofilms using environmental scanning electron microscopy192
Environmental scanning electron microscopy (ESEM) was used to image biofilm communities. A193
FEI Quanta 200 ESEM was used under a low vacuum (<0.83 torr), permitting interrogation of194
putative biofilm structures and microcolonies whilst conserving the hydrated state of the sample.195
Filters were sectioned both transversally and horizontally to ensure that representative images were196
obtained.197
198
Determination of antimicrobial susceptibility in planktonic culture199
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were200
determined axenic planktonic populations. Briefly, stationary phase cultures of MRSA, S. pyogenes,201
9P. aeruginosa and B. fragilis grown in SWF, were adjusted in fresh sterile SWF media to give a cell202
density of c. 1 x 106 CFU/ml. Inocula were dispensed (100 µl) in wells of a flat bottom 96 well203
microtitre plate within 30 min. of preparation. Stock antimicrobial solutions were prepared in SWF204
and dispensed (100 µl) into the first column containing bacterial inocula in the microtitre plate.205
Doubling dilutions of solutions were then made. Plates were incubated in a wet box at 37°C for 24 h.206
The MIC endpoint was determined as the lowest concentration of antimicrobial at with no visible207
growth. The MBC was determined by transferring 10 µl of inocula (that showed no growth) and spot208
plating onto agar plates. Agar plates were incubated for 24 h and then examined for colony growth.209
The MBC endpoint was determined as the lowest concentration that resulted in no visual growth of210
colonies.211
212
Assessment of differential antisepsis in the wound model system213
To assess the effect of the selected antiseptic agents on biofilm communities a series of basal214
perfusion models were set up. Concentrations commonly utilized topically in wound care215
(Bolton 2006, Burks 1998, Butcher 2012, Fong and Wood 2006, Goldenheim 1993) were used that216
were in all cases greater than the corresponding MICs of the test bacteria. These were povidone-217
iodine (10% w/v); polyhexamethylene biguanide (PHMB) (0.5 % v/v) and silver acetate (0.05 %218
w/v). Once systems were established, one untreated filter was removed on day 1 (baseline) and219
viable counts performed as previously described. The perfused media were then supplemented with220
the antimicrobial of interest (added to media to produce the desired concentration) and systems were221
fed with the antimicrobial dosed SWF at rate of 1.5 ± 0.1 ml h-1 by peristaltic pump for the222
remainder of the model run. Filters were removed daily, and viable counts performed as previously223
described.224
225
226
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227
Statistical Analysis228
Data analysis was conducted using a linear mixed-effects model to analyse the average bacterial229
count over time to answer two questions. The first pertained to the stability of the model and the230
second the effect of each treatment against the control. For both questions, a step-wise nested231
modelling approach was taken where after each step a p-value from the likelihood ratio-test was232
reported.233
234
For model stability we first analysed the technical replicates and assumed they are independent from235
each other; that is, we ignored which biological replicate and which bacteria the technical replicate236
was from. We then assessed the importance of knowing which biological replicate the technical237
replicates belonged to. The final step assessed the importance of knowing which bacteria the238
biological replicate belonged to. For the assessment of treatment effect, the model stability data239
(control data) was pooled with the treated data for each treatment. This pooled data was first240
analysed by ignoring whether the data was from treated or control group. We then assessed the241
importance of knowing for which time-series belonged to the control versus treated group. For each242
treatment we reported the size of the effect compared to control as a % drop with 95% confidence243
intervals. All data was Log10 transformed for the analysis and was conducted in Rv3.1.1 using the244
nlme library.245
246
Results247
Developing, Characterising and Optimising the Basally Perfused Model248
Relative fitness assay249
The growth of wound bacteria in binary culture was assessed using monoacetate filters and SFW in a250
competition assay. A relative fitness close to 1.0 was achieved for all combinations (Table 1). Values251
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below 1.0 would indicate that the bacterium was less competitive than its congener. Values above252
1.0 indicate the advantageous growth of the organism in co-culture, at the cost of growth of the other253
organism. A small reduction in the relative fitness was observed for B. fragilis when combined with254
all organisms. This reduction was however interpreted as a feature of the growth of this bacterium in255
relative fitness model due to the requirement for anaerobiosis. Overall data indicate that stable256
maintenance of the consortium was achievable.257
258
Inoculation and population stability259
Using a sequential inoculation approach, defined communities were established within 24 h after the260
final inoculation phase, with each individual species maintaining dynamic stability for a further 8 d261
(Figure 3). Bacterial populations obtained an overall mean density of c. 6 Log10 CFU/mm3 with262
values of c. 6 Log10 CFU/mm3 (0.87 sd) for MRSA, c. 5 Log10 CFU/mm3 (0.68 sd) for S. pyogenesis,263
c. 8 Log10 CFU/mm3 (1.07 sd) for P. aeruginosa and c. 6 Log10 CFU/mm3 (0.74 sd) for B. fragilis.264
265
Microbial population stability within biofilm models266
The step-wise inclusion of each source of variability in the analysis of the average bacterial count267
over time for the Model Stability data set can be seen in Table 2. Data suggests that knowing which268
technical replicate is associated with which biological replicate is important and subsequently269
knowing which biological replicate belongs to which bacteria is also important. Overall this suggests270
that the within bacteria variability is lower than the between bacteria variability which implies the271
experimental system is stable in that it can distinguish between different bacteria.272
273
Homogeneity of microbial populations across filters274
To assess the homogeneity of population densities in each 5mm x 5mm monoacetate filters were275
relative to each other at the same time point, communities were grown to a specific timed endpoint276
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and viable counts performed. Table 3 shows the mean, maximum, minimum and standard deviations277
of viable counts from four filters at each time point. Statistical significance was determined using278
analysis of variance (ANOVA) combined with post-hoc analysis of least significant difference279
(LSD) test to determine significant difference. No significant difference was found between viable280
counts of MRSA, S. pyogenes, P. aeruginosa or B. fragilis between the filters on each day sampled.281
The basal perfusion model was validated longitudinally and cross-sectionally; a dynamic steady state282
was achieved up to 8 d in independent runs and comparable populations were obtained between283
filters harvested at the same time point.284
285
Antimicrobial exposure286
Minimum inhibitory and minimum bactericidal concentrations287
Data in Table 4 show the minimum inhibitory and minimum bactericidal concentrations for288
povidone-iodine, PHMB and silver acetate determined for each organism. All MICs were lower than289
selected for assessment in the biofilm model, which represent concentrations typically used in topical290
wound treatments (Bolton 2006, Burks 1998, Butcher 2012, Goldenheim 1993).291
292
Antimicrobial effects on four-species biofilm consortia293
The impact of the exposure regimens on the individual populations in the bacterial consortia varied294
considerably (Figures 4-6). For both PHMB and povidone-iodine, populations of Group A295
Streptococcus became undetectable after dosing, with communities of MRSA and B. fragilis also296
significantly affected, although viable populations of these organisms were detected with increasing297
frequency (across replicate systems) towards the later phases of dosing in replicated experiments298
(day 4 onwards). Data for silver acetate dosing show that overall bacterial viability for P. aeruginosa299
remained largely unaffected, with cell counts remaining relatively stable for the remainder of the300
model runs. There was however, considerable reduction in the viable populations of MRSA, Group301
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A Streptococcus and B. fragilis 24 h after dosing began but the detectable populations stayed302
relatively stable for the remainder of the study albeit at a numerically lower density. The overall rank303
order of effectiveness for the antimicrobials was povidone-iodine > PHMB > silver acetate. The304
analysis of the effect of each treatment on the average bacterial count over time can be seen in Table305
5. The magnitude of the treatment effect on the bacterial population varies across the treatments. The306
largest reduction in bacterial count was seen for povidone-iodine (57%) followed by PHMB (44%)307
and then silver acetate (27%).308
309
Biofilm imaging310
ESEM revealed afferent bacteria and microcolonies of proportions, along with and putative biofilm311
EPS throughout inoculated filters (Figure 7 b-d). Comparisons with the negative control filter312
(Figure 7a) indicate that the microcolonies and putative EPS observed were the result of inoculation313
and environmental conditions of the model and were not an artifact of the filter structure or media.314
315
Discussion316
There is considerable interest in the development of effective regiments for the management of317
biofilms within complex wounds. In vivo and in vitro biofilm models have previously been used as318
research tools in this field. An issue of concern with biofilm models however is the ability to319
maintain populations comprising bacteria with distinct oxygen requirements in a system that320
facilitates the effects of antimicrobial compounds to be determined. With the broad aim of providing321
a platform in which this could be explored, an in vitro wound biofilm model was developed that322
reproduces the basolateral nutrient delivery of wounds, and which supports the growth of a defined323
consortium comprising of organisms of interest in wounds with distinct antimicrobial324
susceptibilities, general physiology and growth requirements.325
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Before designing the wound basal perfusion model, currently available model systems were326
assessed for their potential use. These included the Multiple Sorbarod Device (Ledder et al. 2006)327
and a Flat-Bed Perfusion Biofilm model (Thorn and Greenman 2009). To develop a model suitable328
for the required application, selected characteristics of these systems were adopted, including the use329
of filters as substrata and a nutrient delivery system which supplied nutrient media to the basally.330
The developed system combines a continuous perfusion, similar to exudate flow in a wound, with331
eight sampling positions to support the continuous assessments of a treatment over time or a single332
treatment point with multiple replicates.333
In preliminary investigations, when models were concomitantly inoculated with MRSA, S.334
pyrogens, P. aeruginosa and B. fragilis, all species were initially detectable. However, after 24 h,335
MRSA and S. pyogenes rapidly declined and became undetectable, whilst populations of P.336
aeruginosa and B. fragilis expanded. To determine if the test bacteria could in principle grow in337
consortia under optimised conditions, relative fitness assays were performed in which the test338
organisms were grown together in all binary combinations with no evidence of specific growth339
inhibition. These data supported the initial observations of 24 h of growth in a prototype system,340
where viable Gram-positive organisms were detectable within 24 h of inoculation. Based on these341
observations a sequential inoculation procedure was developed in which MRSA and S. pyogenes342
were established prior to the introduction of the Gram-negative organisms including the obligate343
anaerobe, Bacteroides fragilis after 24 h. Using this approach, all four organisms became established344
within defined species wound-type biofilms for up to 8 d.345
The inclusion of eight sampling positions in the biofilm model facilitated the collection of346
multiple baseline and treatment samples to monitor stability and reproducibility. The similarity in347
population densities between replicated model runs indicates that baseline values and daily sampling348
would provide a suitable platform through which to test the efficacy of antimicrobial therapies such349
as wound dressings over a 7 d period.350
15
Three topical wound treatments with distinct modes of action were investigated; silver351
acetate, povidone-iodine and polyhexamethylene biguanide (PHMB) against the four-species352
consortium. For povidone-iodine and PHMB, concentrations of 10% and 0.5% (respectively) were353
selected based upon concentrations typically used in topical wound treatments (Burks 1998, Butcher354
2012, Goldenheim 1993). Defining a relevant concentration for silver was however, more355
complicated, with previous reports of various silver compounds such as silver acetate, silver nitrate356
and nanoparticles being used at various concentrations in a range of commercially available wound357
dressings (Bolton 2006, Fong and Wood 2006). Following a literature review, silver acetate was358
selected and used at the highest soluble concentration achievable in the growth medium, which was359
greater than the MIC for silver acetate for each test bacterium.360
Based on replicated determinations, the rank order of effectiveness for the antimicrobials in361
planktonic susceptibility tests was (highest to lowest) silver acetate > povidone iodine > PHMB. For362
biofilm communities however, it was povidone-iodine > PHMB > silver acetate. Possible reasons for363
this disparity include the fact that i) the mechanisms that underlie antimicrobial tolerance with364
biofilms are partly distinct from those that are assessed in planktonic susceptibility tests and ii) that365
povidone iodine was applied to the biofilms at 10% (w/v), polyhexamethylene biguanide at 0.5% and366
silver acetate at 0.05% (w/v), therefore planktonic susceptibility data (MIC and MBC) cannot367
necessarily be used to predict to the outcome of biofilm exposure. These two considerations are of368
relevance in the assessment of the effectiveness of antimicrobials for wound care, reinforcing the369
need to consider the biofilm phenotype in antimicrobial tests and to consider that the concentrations370
of distinct antimicrobial compounds used in wound care vary for reasons that include formulation,371
toxicity and regulation.372
For data generated using the wound model, both povidone-iodine and PHMB had the greatest373
impact on MRSA, B. fragilis and Group A Streptococcus, with the latter undetectable in both the374
povidone-iodine and PHMB dosed systems from second day of dosing. For povidone-iodine, PHMB375
16
and silver acetate-dosed systems; P. aeruginosa was detected throughout, with silver acetate being376
the least effective of the antimicrobials tested against this bacterium. In some cases, following the377
initial inactivation of bacteria, partial recovery of cell counts was observed during continual378
exposure to antimicrobials. This was apparent following initial exposure and was notable for P.379
aeruginosa during exposure to povidone-iodine and PHMB and for MRSA during exposure to380
PHMB and silver acetate.381
When a microbial community is exposed to an antimicrobial agent, organisms will generally382
be inactivated in order of their susceptibility. The well documented tolerance of biofilms towards383
antimicrobials may increase this effect, since it is less likely that a biofilm community will be384
completed inactivated than the same organisms growing in dispersed, planktonic form. An additional385
consideration is that the tolerance conferred by biofilm growth may be greater for some organisms386
than for others. In the current context, the recalcitrance of P. aeruginosa (Pedersen, 1992; Gilbert et387
al., 2002; Walters et al., 2003), its tendency to form biofilms, and the recalcitrance of those biofilms388
once developed, has been widely reported. Thus, the relative susceptibility of bacteria observed in389
the current study, and the survival of P. aeruginosa in exposed biofilms could be largely predicted390
based on known features of this bacterium. The observed inactivation kinetics could be explained by391
phenotypic adaptation within the biofilm, whilst the varied tolerance to antimicrobial exposure392
observed in the basal perfusion model against the three compounds resembles that previously393
reported by Forstner et al. (2013) using a porcine wound model. Since distinct bacteria often394
exhibited distinct antimicrobial susceptibly profiles to antiseptics as well as to antibiotics, such395
variable antibacterial effects may be an important but relatively little studied variable in wound396
antisepsis (Davis et al. 2006, James et al. 2008, Roy et al. 2014, Saye 2007).397
In conclusion, the primary objective of the current investigation was to develop an in vitro398
biofilm model which would i) support the growth of a mixed species consortia; ii) could be used399
model antisepsis and iii) would facilitate the establishment of replicated biofilm consortia for400
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temporal studies. A defined species biofilm consortium containing aerobic, facultative and anaerobic401
species was grown reproducibly using the basally perfused model. The effect of topical wound402
antimicrobials was examined and variable susceptibility in the four test bacteria was evident in403
biofilm consortia despite concentrations used being considerably higher than planktonic404
susceptibility, a phenomenon often associated with biofilms.405
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Figure 1. A diagrammatical cross-sectional view of the basal perfusion model illustrating the media553
delivery and waste outflow. The filters on which biofilms are grown are 5mm x 5mm in size and are554
placed within the individual holes (8 in total) of the central fluid basin. The upper section and lower555
section of these individual holes are separated by a small rim/ledge upon which the filter rest.556
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Figure 2. A diagrammatical view of the individual components (A) and combined (B) components565
of the basal perfusion wound model.566
567
A Lid
Central receptacle
Waste reservoir
Pyrex glass outer casing
B
23
568
569
Figure 3. Population densities of the four species wound consortia grown and maintained for 8 d in570
the three independent basal perfusion models. The boxes represent the interquartile range with the571
lower and upper boundaries of the boxes representing quartiles 1 and 3; the central line is the572
median. The whiskers represent the maximum and minimum values. Data represent mean and ranges573
for three independent experiments. Detection threshold, <1.0 Log10 CFU/mm3574
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Figure 4. Population densities the four species wound consortia grown in the basal perfusion models581
and exposed to 10% povidone-iodine. Single horizontal lines indicate viable count data for one582
replicate above the detection threshold. See legend to Figure 3.583
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Figure 5. Population densities the four species wound consortia grown in the basal perfusion models605
and exposed to 0.5% PHMB. See legend to Figure 3.606
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Figure 6. Population densities the four species wound consortia grown in the basal perfusion models614
and exposed to 0.05 % silver acetate. See legend to Figure 3.615
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Figure 7. ESEM images showing (a) an uninoculated filter; (b) adherent bacteria (mainly rod morphology);623
(c) a microcolony and (d) a larger colony/biofilm of coccoid bacteria on filter samples taken from inoculated624
models.625
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Table 1. The relative fitness of organisms in the modified competition assay635
Relative fitness of → 
versus ↓
Bacterium
MRSA S. pyogenes P. aeruginosa B. fragilis
MRSA na 1.05 (0.02) 0.96 (0.09) 0.83 (0.03)
S. pyogenes 0.95 (0.04) na 1.13 (0.04) 0.84 (0.03)
P. aeruginosa 1.04 (0.14) 0.89 (0.07) na 0.78 (0.15)
B. fragilis 1.21 (0.05) 1.19 (0.10) 1.28 (0.15) na
na, not applicable. Data are means (SEM) of three separate experiments.636
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Table 2. The goodness of fit value, -2LL, for each iteration of the model, together with p-value from640
the likelihood ratio test for model stability assays641
642
643
644
645
646
Replicate type -2LL (p-value)
Technical Replicates (1) 567
Technical Replicates in Biological replicates (2) 542 (2 v 1: p < 0.001)
Technical Replicates in Biological replicates in type of Bacteria (3) 533 (3 v 2: p = 0.004)
30
Table 3. The mean, maximum, minimum and standard deviation of population densities from four separate mono-acetate filters647
sampled at the same time point648
Data are Log10 CFU per mm3.649
Day
Bacterium
MRSA S. pyogenes P. aeruginosa B. fragilis
Mean Max Min Stdev Mean Max Min Stdev Mean Max Min Stdev Mean Max Min Stdev
1 7.72 7.93 7.52 0.17 8.58 9.10 8.25 0.38 9.52 9.60 9.43 0.08 9.32 9.35 9.26 0.04
2 7.73 7.84 7.68 0.07 7.62 7.73 7.49 0.11 9.53 9.62 9.43 0.10 9.28 9.32 9.23 0.04
3 7.31 7.59 7.11 0.22 7.42 7.60 7.24 0.17 9.45 9.47 9.43 0.02 9.12 9.17 9.04 0.06
4 7.28 7.38 7.19 0.09 7.62 7.76 7.50 0.11 9.31 9.35 9.25 0.04 9.24 9.39 9.07 0.13
5 7.34 7.52 7.24 0.13 7.08 7.22 6.96 0.11 9.26 9.42 9.05 0.16 8.92 9.09 8.65 0.19
6 7.50 7.68 7.26 0.20 7.00 7.20 6.81 0.16 9.40 9.48 9.36 0.05 9.13 9.57 8.94 0.30
7 7.06 7.68 6.46 0.66 6.99 7.24 6.77 0.20 9.37 9.39 9.35 0.02 8.07 8.22 7.93 0.12
8 6.45 6.55 6.23 0.15 7.62 8.08 6.96 0.53 9.46 9.51 9.40 0.06 7.98 8.04 7.92 0.06
31
650
Table 4. Planktonic susceptibility determined in simulated wound fluid651
652
653
654
655
656
657
658
659
660
All concentrations are mg/L. Standard deviations are given in parenthesis, nd, not determined (>1.25mg/l).661
Data are means from three separate determinations.662
663
Bacterium
Planktonic susceptibility
MIC MBC
PHMB Silver acetate Povidone-iodine PHMB Silver acetate
Povidone-
iodine
MRSA 7.94 (2.75) 0.08 5210 (1800) 101 (44.01) 1.25 25000
S. pyogenes 4.76 0.02 490 (4100) 22.23 (14.55) 0.26 (0.09) 20839 (7220)
P. aeruginosa 152 0.04 8330 (3610) 2032 (704) 1.25 25000
B. fragilis 6.35 (2.75) 0.07 (0.02) 3130 25.00 nd 25000
32
664
Table 5. The difference in -2LL between each treatment, control and model stability showing p-values derived from the likelihood665
ratio test for the treatment assays666
667
668
669
670
671
672
673
674
CI, confidence interval.675
Treatment -2LL Drop (p-value) % Relative Drop (95% CI)
Povidone-iodine 46 (p<0.001) 57 (51, 63)
PHMB 27 (p<0.001) 44 (35, 53)
Silver acetate 12 (p<0.001) 27 (15, 39)
